AMGNQ2 20261/5Estimate vs Actual
Earnings per Share
$6.29
+ 12.0% vs Estimate
Surprise as recorded in the analysis; the estimate itself is not on the calendar.
Amgen Inc Q2 2026 · Story
Read the quarter card by card, ready to share.
AMGNQ2 20261/5AMGNQ2 20262/5Guidance
Full-Year Revenue
- Company Guidance
- 38.2 – 39.4 billion
- Market Estimate
- 37.8 billion
Midpoint 2.6% Above Estimate ▲
Full-Year Adjusted EPS
- Company Guidance
- 22.3 – 23.5 $
- Market Estimate
- 22.39 $
Midpoint 2.3% Above Estimate ▲
Full-Year GAAP EPS
- Company Guidance
- 15.80 – 17.08 $
▲ 65% YoY
AMGNQ2 20263/5Price Reaction
First Full Session
+ 4.6%
From the report-day close to the next session's close.
AMGNQ2 20264/5In 30 Seconds
Revenue rose 10% year over year to $10.05B, and adjusted EPS of $6.29 beat expectations by about 12%.
- Full-year revenue guidance was raised to $38.2-39.4B, but Prolia and Xgeva shrank 33% under biosimilar pressure.
- The stock rose 4.57% to $407.83 the next session as the guidance raise answered worries about patent losses.
First point of the analysis's “In 30 Seconds”.
Full AnalysisAMGNQ2 20265/5Score
78/ 100
ViewBUY
Not Investment Advice